Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Ans – page 86

1 400 clinical trials in Ans, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Ans at a glance
1 400
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 400 trials in Ans

Open in trial search

Acute myeloid leukaemia+1

Not recruiting

Study of Ivosidenib or Enasidenib with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with IDH1 or IDH2 Mutation

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Enasidenib Mesilate
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study Comparing Two Treatment Sequences of CDK4/6 Inhibitors (Abemaciclib, Palbociclib, or Ribociclib) in Hormone Receptor Positive Advanced Breast Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:BOOG Study Center B.V.

Breast cancer stage III+2

Not recruiting

Study of Trastuzumab, Pertuzumab, and Chemotherapy Combination with Response-Guided Treatment for Patients with HER2-Positive Breast Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:BOOG Study Center B.V.

Study comparing chemotherapy with or without radiation therapy in patients with resectable gastroesophageal junction cancer using docetaxel, oxaliplatin, fluorouracil and calcium folinate

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Heidelberg University

Colorectal cancer+1

Not recruiting

Study on Bevacizumab and Drug Combination for Patients with Resectable Colorectal Peritoneal Metastases

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Catharina Ziekenhuis Stichting

Study on the Effects and Safety of Buloxibutid for Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Buloxibutid
  • Sponsor:Vicore Pharma AB

Cholangiocarcinoma+1

Not recruiting

Study on Gemcitabine and Cisplatin for Patients After Surgery for Bile Duct or Gallbladder Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:University Medical Center Hamburg-Eppendorf

Ovarian cancer

Not recruiting

Study of olaparib, durvalumab and UV1 combination as maintenance treatment for patients with recurrent ovarian cancer who do not have BRCA mutations

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Alrefimotide
  • Sponsor:Nordic Society Of Gynaecological Oncology Clinical Trial Unit

Neoplasm

Not recruiting

Study of EOS884448, Dostarlimab, and Inupadenant for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:iTeos Belgium

Study of Brentuximab Vedotin Combined with R-DHAP Chemotherapy for Patients with Relapsed or Treatment-Resistant CD30-Positive Diffuse Large B-Cell Lymphoma Who Are Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Brentuximab Vedotin
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Neuroblastoma

Not recruiting

Study on Bevacizumab with Temozolomide and Irinotecan for Children with Relapsed or Refractory Neuroblastoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Bevacizumab
  • Sponsor:The University Of Birmingham

Myelofibrosis+1

Not recruiting

Study of Navtemadlin for Patients with Myelofibrosis Resistant to JAK Inhibitors

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Danazol
  • Sponsor:Kartos Therapeutics Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Ans

What the registry says about research in the country

01 Gastroenterology Research

Clinical investigations focusing on proton pump inhibitor (PPI) de-prescribing strategies for patients with chronic usage patterns. The research explores innovative approaches to manage functional dyspepsia and related conditions.

  • PPI Usage Optimization
  • Digestive Health Management
  • Acid Reflux Treatment

This primary care study evaluates different therapeutic approaches, including on-demand medication use and alternative treatment formulations, to improve patient outcomes in digestive health management.

02 Primary Care Innovation

Groundbreaking research in medication management strategies, specifically targeting long-term PPI use in primary care settings. The study compares various approaches to reduce unnecessary medication dependency.

  • Medication De-prescribing
  • Patient-Centered Care
  • Treatment Optimization

The research aims to establish more effective protocols for managing common digestive conditions while minimizing long-term medication use.

03 Therapeutic Alternatives

Investigation into alternative treatment options for managing heartburn and related gastrointestinal conditions. The study explores the effectiveness of different therapeutic approaches.

  • Alternative Treatments
  • Symptom Management
  • Treatment Comparison

This research evaluates the comparative effectiveness of various treatment strategies, including alginate formulations and flexible dosing schedules.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.